Skip to content


  • Poster presentation
  • Open Access

Structured exploration of clinical trials data - finding the middle way

  • 1
Trials201516 (Suppl 2) :P152

  • Published:


  • Data Mining
  • Specific Data
  • Additional Insight
  • Conservative Approach
  • Usual Model

The traditional statistical analysis of data from clinical trials tends to follow a conservative approach centred around pre-specification, hypothesis testing and regulatory considerations. On the other hand, attempts to take a more exploratory approach are often criticised for being open-ended ‘data dredging’ exercises, lacking pre-specification, and failing to adequately control type I error.

If it is possible to find a ‘middle way’ between these two extremes, we can uncover invaluable additional insights about medicines - whether in development or approved. At AstraZeneca, our Structured Exploration capability was created to do just that. Examining patient-level clinical trials data more thoroughly can: (1) refine the target population for a medicine; (2) enhance our understanding of benefit-risk; (3) reignite the development of a compound otherwise shelved as having insufficient benefit in the overall trial population.

Our implementation of Structured Exploration centers around the selection of two specific data mining methods - Virtual Twins [1] and Inside-Out [2]. Virtual Twins has roots in the field of causal inference and counterfactuals, and provides a flexible framework within which to explore predictive subgroups. Inside-out turns the usual model formulation around, and instead of estimating the treatment effect on each adverse event separately, quantifies the ability of all the adverse events to classify patients to treatment.

Authors’ Affiliations

AstraZeneca, Alderley Park, Cheshire, UK


  1. Foster JC, Taylor JM, Ruberg SJ: Subgroup identification from randomized clinical trial data. Stat Med. 2011, 30: 2867-2880.View ArticlePubMedGoogle Scholar
  2. Southworth H, O'Connell M: Data mining and statistically guided clinical review of adverse event data in clinical trials. J Biopharm Stat. 2009, 19: 803-17.View ArticlePubMedGoogle Scholar


© Weatherall 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.